IDiyas

For the Inventor, By the Inventor

Ludwigshafen, Germany

Horst Koenig

USPTO Granted Patents = 24

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 90(Granted Patents)


Company Filing History:

goldMedal24 out of 10,754 
 
Basf Aktiengesellschaft
 patents

Years Active: 1976-1990

Loading Chart...
24 patents (USPTO):
1. 4918072 - Platelet aggregation inhibiting composition (1990-04-17),
2. 4873246 - 6-(acylaminoaryl)-3(2H)-pyridazinone derivatives, and their use (1989-10-10),
3. 4772598 - 2-aryl-3,4-diazabicyclo(4.n.O)alk-2-en-5-ones for the preparation of an (1988-09-20),
4. 4734405 - Combination product (1988-03-29),
5. 4730042 - Compounds 1 or (1988-03-08),
6. 4663338 - Treatment of viral diseases (1987-05-05),
7. 4636504 - 6-(acylaminoaryl)-3(2H)-pyridazinone derivatives and their use (1987-01-13),
8. 4544562 - 6-Aryl-4,5-dihydro-3(2H)-pyridazinones, and their use as (1985-10-01),
9. 4474785 - 2-Aryl-3,4-diazabicyclo[4.n.O]alk-2-en-5-ones, and compositions for (1984-10-02),
10. 4415571 - Carbamate dihydropyridazinones, their preparation and therapeutic agents (1983-11-15),
11. 4410529 - Novel dihydropyridazinones, their preparation and therapeutic agents (1983-10-18),
12. 4376771 - 6-(p-Acylaminophenyl)-4,5-dihydropyridaz-3-ones and therapeutic agents (1983-03-15),
13. 4280008 - Chirally substituted 2-imidazolin-5-ones (1981-07-21),
14. 4269990 - 1-Acyl-2-imidazolines and their manufacture (1981-05-26),
15. 4267187 - Aminopropanol derivatives of 2-(0-hydroxyphenyl)-pyrrole (1981-05-12),

Title: Innovations and Contributions of Horst Koenig in Thromboembolic Disorder Treatment

Introduction

Horst Koenig, a prominent inventor based in Ludwigshafen, Germany, has made significant contributions to the field of medicinal chemistry, particularly in developing innovative treatments for thromboembolic disorders. With a remarkable portfolio of 24 patents, Koenig has established himself as a key player in pharmaceutical research and development.

Latest Patents

Among his latest innovations, Koenig has developed a series of groundbreaking patents. One notable patent focuses on a platelet aggregation inhibiting composition, which comprises a combination of phenylacetonitrile and a pyridazinone derivative. This invention aims to treat thromboembolic disorders, providing a novel approach to patient care. Another important patent involves the novel 6-(acylaminoaryl)-3(2H)-pyridazinone derivatives. These compounds, characterized by a specific formula, exhibit thrombocyte aggregation-inhibiting activity and have been meticulously described in terms of their preparation and potential applications.

Career Highlights

Horst Koenig is currently associated with BASF Aktiengesellschaft, a leading company in the chemical industry, where he continues to innovate and push the boundaries of pharmaceutical science. His dedication and expertise in the field have led to significant advances in drug development and therapeutic methodologies.

Collaborations

Throughout his career, Koenig has collaborated with esteemed colleagues such as Josef Gries and Marco Thyes. Their combined efforts have fostered an environment of innovation and research excellence, contributing to the success of their projects and the advancement of medical treatments.

Conclusion

Horst Koenig's contributions to the field of medicinal chemistry and his impressive track record of patents underscore his role as a leading inventor in the fight against thromboembolic disorders. His work not only enhances our understanding of these conditions but also paves the way for new therapeutic options, benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…